- Conditions
- Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
- Interventions
- Ultevursen, Sham-procedure
- Drug · Other
- Lead sponsor
- Laboratoires Thea
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 10
- States / cities
- San Diego, California • San Francisco, California • Miami, Florida + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 256
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Submacular Vascularized Pigment Epithelial Detachments
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Southern California Desert Retina Consultants, MC
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Palm Desert, California • Rapid City, South Dakota
- Conditions
- Uveitis
- Interventions
- Fluocinolone Acetonide
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Stargardt Disease
- Interventions
- Gene Therapy-vMCO-010
- Biological
- Lead sponsor
- Nanoscope Therapeutics Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Miami, Florida • McAllen, Texas
- Conditions
- Intravitreal Injection, Pain
- Interventions
- Visual analog scale (VAS) of pain to evaluate the discomfort participants experience.
- Other
- Lead sponsor
- New York City Health and Hospitals Corporation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
- Interventions
- THR-687 dose level 1, THR-687 dose level 2, THR-687 dose level 3
- Drug
- Lead sponsor
- ThromboGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Winter Haven, Florida • Indianapolis, Indiana + 4 more
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 54
- States / cities
- Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more
- Conditions
- Geographic Atrophy
- Interventions
- Sham, Lampalizumab
- Other · Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 36
- States / cities
- Mesa, Arizona • Tucson, Arizona • Springdale, Arkansas + 33 more
- Conditions
- Choroidal Neovascularization, Presumed Ocular Histoplasmosis
- Interventions
- EYLEA (Aflibercept) intravitreal injection
- Drug
- Lead sponsor
- Retina Research Institute, LLC
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 3
- States / cities
- St Louis, Missouri
- Conditions
- Age-Related Macular Degeneration
- Interventions
- 0.5 mg of DE-122, 1.0 mg of DE-122, 2.0 mg of DE-122, 4.0 mg of DE-122
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 5
- States / cities
- Mountain View, California • Walnut Creek, California • Jackson, Michigan + 2 more
- Conditions
- Retinopathy, Diabetic
- Interventions
- Aflibercept Injection, Sham injection
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Retinal Vein Occlusion, Macular Edema
- Interventions
- Ozurdex
- Drug
- Lead sponsor
- Retina Macula Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Fluocinolone Acetonide
- Drug
- Lead sponsor
- Alimera Sciences
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Anesthesia, Local
- Interventions
- AG-920, Placebo
- Drug
- Lead sponsor
- American Genomics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Diabetic Macular Edema
- Interventions
- bevacizumab, PASCAL Endpoint Management (EpM) laser treatment
- Drug · Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Telangiectasia
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Intravitreal Injection Patients
- Interventions
- Vigamox
- Drug
- Lead sponsor
- Illinois Retina Associates
- Other
- Eligibility
- 21 Years to 100 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Harvey, Illinois
- Conditions
- Exudative Macular Degeneration
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Rishi Singh
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Proliferative Vitreoretinopathy
- Interventions
- ADX-2191 (intravitreal methotrexate 0.8%), Standard surgical care procedure
- Drug · Other
- Lead sponsor
- Aldeyra Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 18 more
- Conditions
- Fibrovascular Pigment Epithelial Detachment
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Vitreous -Retina- Macula Consultants of New York
- Other
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Vitreomacular Adhesion
- Interventions
- Ocriplasmin 125µg, Placebo
- Drug
- Lead sponsor
- ThromboGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 20
- States / cities
- Campbell, California • San Francisco, California • Santa Barbara, California + 17 more
- Conditions
- Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Degeneration
- Interventions
- Gene Therapy product-MCO-010
- Biological
- Lead sponsor
- Nanoscope Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Pensacola, Florida • Fargo, North Dakota + 2 more
- Conditions
- Anesthesia, Local, Intravitreal Injection, Macular Edema, Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema
- Interventions
- Recens Cooling Anesthesia Device
- Device
- Lead sponsor
- Recens Medical, Inc.
- Industry
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Reno, Nevada • Houston, Texas
- Conditions
- Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Interventions
- Varying needle size with intravitreal ranibizumab or aflibercept
- Procedure
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania